Australia's largest stock trading and investment forum Australia's #1 stock forum

RAC

1.35%

$1.88 race oncology ltd

Pillar 1 - FTO (new thread), page-297

First 297 Last

Share
Profile

Follow
Hunterr

5,594 Posts.

1262

04/03/21

13:46

Post #: 51517012
Share

Originally posted by Titans19 ↑

ha... the only negative opinions I have are on how the finances are done. I hope now given where the share price is most understand my frustrations over the past 12 months.

I've always been very bullish on what we know for Bisantrene and the science.

If I had any 'negative' opinion on the science it would be:

Pillar 1 - just because it worked in mice it doesn't mean it'll work in humans. (I am very optimistic though).. We also need to consider correlation or causation. Although, I like the potential hypothesis for Pillar 1 and I again am very optimistic.

Pillar 2 - Previous trials were a fail due to poor trial design so I don't give too much credit to them. Plus new treatments have set a very high bar, and liposomal treatment helps with cardio toxicity therefore the cardio benefit isn't as great if efficacy isn't there (IMO - I would always roll the die on cardio if survival was higher). However, after looking at the MST report and their suggested trial, plus some personal experiences we are going through with a friend resulting in me doing more scientific research (as best I can), I am again very optimistic on this Pillar as well.

Pillar 3 - well there's no negative to this Pillar. It's locked in in my opinion. I just hope they do a good trial design, get the PRV and get this approved as soon as possible. I would like to see Bisantrene approved and treating people for AML and also used off label.

That's about as good as I can get for 'negative' opinions on the science... I have a massive negative list on the financials! ha..

Plus I don't like to count my chickens before they hatch. Especially with the overall risks involved in Pillar 1 and 2 (trial design, efficacy, competition, time, etc).

IMO, DYOR, etc

[/QUOTE
To ease your mind a little with the one concern you may have.

Most of the mice and rats used in medical trials are inbred so they are almost identical genetically helping to make the results of medical trials more uniform. Another reason they're used as models in medical testing is that their genetic, biological and behavior characteristics closely resemble those of humans.

Many symptoms of human conditions can be replicated through rats and mice.

Expand

Most of the mice and rats used in medical trials are inbred so they are almost identical genetically helping to make the results of medical trials more uniform. Another reason they're used as models in medical testing is that their genetic, biological and behavior characteristics closely resemble those of humans.

Many symptoms of human conditions can be replicated through rats and mice.
From Internet that should ease your mind a little

Last edited by Hunterr: 04/03/21

RAC Price at posting: $3.78 Sentiment: Buy Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

There are more pages in this discussion • 2,678 more messages in this thread...

First 297 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.88		Change 0.025(1.35%)		Mkt cap ! $319.4M

Open	High	Low	Value	Volume
$1.85	$1.89	$1.85	$74.38K	39.92K

Buyers (Bids)

No.	Vol.	Price($)
1	18943	$1.85

Sellers (Offers)

Price($)	Vol.	No.
$1.88	199	1

View Market Depth

No.	Vol.	Price($)
1	18943	1.850
1	2500	1.830
2	987	1.820
8	16776	1.800
1	11000	1.780

Price($)	Vol.	No.
1.875	199	1
1.895	3000	1
1.940	5148	2
1.950	12000	1
1.990	4701	2

Last trade - 16.10pm 17/07/2024 (20 minute delay)

RAC (ASX) Chart

Pillar 1 - FTO (new thread), page-297

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pillar 1 - FTO (new thread), page-297

Top Stories

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News